Comparison of treatments for congenital nonobstructive nonhaemolytic hyperbilirubinaemia.
A patient with Crigler-Najjar disease has survived with the help of phototherapy to the age of 2 years without neurological damage. Because long periods of phototherapy are a threat to normal development, a search was made for supplementary treatments. Cholestyramine and a high fat diet were effective, and possibly also aspartic acid. Maintenance therapy with cholestyramine allowed the amount of phototherapy given to be reduced.
D000362:Agar / Q000627:therapeutic use; D001224:Aspartic Acid / Q000627:therapeutic use*; D001663:Bilirubin / Q000032:analysis / Q000097:blood / Q000652:urine; D001925:Brain Damage, Chronic / Q000628:therapy; D002675:Child, Preschool; D002792:Cholestyramine Resin / Q000627:therapeutic use*; D004041:Dietary Fats; D005078:Exchange Transfusion, Whole Blood; D005243:Feces / Q000032:analysis; D005260:Female; D006801:Humans; D006933:Hyperbilirubinemia, Hereditary / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D007223:Infant; D007231:Infant, Newborn; D010634:Phenobarbital / Q000627:therapeutic use; D010789:Phototherapy; D013577:Syndrome; D014539:Uridine Diphosphate Sugars / Q000627:therapeutic use
D004041:Dietary Fats; D014539:Uridine Diphosphate Sugars; D002792:Cholestyramine Resin; D001224:Aspartic Acid; D000362:Agar; D001663:Bilirubin; D010634:Phenobarbital